{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:24:28Z","timestamp":1789428268831,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejso.2026.111403","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:24:31Z","timestamp":1768235071000},"page":"111403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Surgical complications after therapeutic lymph node dissection in stage III\u2013IV melanoma: impact of neoadjuvant immunotherapy"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0609-1664","authenticated-orcid":false,"given":"Julia V.C.","family":"Lytchi\u00e9r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis I.","family":"Okur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktor","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Falk Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ejso.2026.111403_bib1","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejso.2026.111403_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111403_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.ejso.2026.111403_bib4","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejso.2026.111403_bib5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111403_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325\/KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2026.111403_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study","volume":"115","author":"Helgadottir","year":"2023","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"43","key":"10.1016\/j.ejso.2026.111403_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390614","article-title":"Neoadjuvant immunotherapy in melanoma: the paradigm shift","author":"Hieken","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.ejso.2026.111403_bib9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.ejso.2026.111403_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA2","article-title":"Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: the phase 3 NADINA trial","volume":"42","author":"Blank","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2026.111403_bib11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ejso.2026.111403_bib12","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111403_bib13","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.111403_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115485","article-title":"Neoadjuvant immunotherapy for patients with resectable stage III\/IV cutaneous melanoma \u2013 a Swedish retrospective real-world study (NEO-MEL)","volume":"224","author":"Nelson","year":"2025","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2026.111403_bib15","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41591-024-03077-5","article-title":"Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial","volume":"30","author":"Long","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.111403_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2023.03.003","article-title":"Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery","volume":"185","author":"Zijlker","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.111403_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable stage III melanoma: the phase II NeoACTIVATE trial","volume":"15","author":"Hieken","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ejso.2026.111403_bib18","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.7150\/jca.72210","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced malignant melanoma: a meta-analysis on monotherapy Vs combination therapy","volume":"13","author":"Pradeep","year":"2022","journal-title":"J Cancer"},{"issue":"7","key":"10.1016\/j.ejso.2026.111403_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1308\/147870811X13137608455019","article-title":"Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM","volume":"93","author":"Egberts","year":"2011","journal-title":"Ann R Coll Surg Engl"},{"issue":"8","key":"10.1016\/j.ejso.2026.111403_bib20","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1245\/s10434-024-15274-0","article-title":"The effect of neoadjuvant systemic therapy on surgical outcomes after lymph node dissections for stage III melanoma; an Australian cohort","volume":"31","author":"Zijlker","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111403_bib21","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1245\/s10434-010-1026-z","article-title":"Prospective assessment of postoperative complications and associated costs following Inguinal lymph node dissection (ILND) in melanoma patients","volume":"17","author":"Chang","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111403_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1245\/s10434-016-5461-3","article-title":"Morbidity after inguinal lymph node dissections: it is time for a change","volume":"24","author":"Faut","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111403_bib23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.ejso.2014.01.019","article-title":"Surgical wound complications after groin dissection in melanoma patients \u2013 a historical cohort study and risk factor analysis","volume":"40","author":"Stuiver","year":"2014","journal-title":"Eur J Surg Oncol EJSO"},{"issue":"1","key":"10.1016\/j.ejso.2026.111403_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jamcollsurg.2008.08.029","article-title":"Incidence of clinically significant seroma after breast and axillary surgery","volume":"208","author":"Boostrom","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2026.111403_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.breast.2018.04.005","article-title":"Delay of adjuvant radiotherapy due to postoperative complications after oncoplastic breast conserving surgery","volume":"39","author":"Hillberg","year":"2018","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.ejso.2026.111403_bib26","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.3390\/curroncol29080446","article-title":"Higher rate of lymphedema with inguinal versus axillary complete lymph node dissection for melanoma: a potential target for immediate lymphatic reconstruction?","volume":"29","author":"Deban","year":"2022","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111403_bib27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3390\/life11101036","article-title":"Neoadjuvant immunotherapy in resectable non-small cell lung cancer. A narrative review","volume":"11","author":"Gatteschi","year":"2021","journal-title":"Life"},{"issue":"2","key":"10.1016\/j.ejso.2026.111403_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00238-021-01839-9","article-title":"Complications after surgery for malignant melanoma do not delay further treatment","volume":"45","author":"Munkhammar","year":"2022","journal-title":"Eur J Plast Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:50:09Z","timestamp":1775602209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0748798326000223"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111403","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical complications after therapeutic lymph node dissection in stage III\u2013IV melanoma: impact of neoadjuvant immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111403"}}